Evidence map›Paper›PMID 40898684›Full record

ArticleNeurodegenerative disease management2026

The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.

Yahui Zhu, Jiongming Bai, Hongfen Wang, Mao Li, Fei Yang, Xinyuan Pang, Rongrong Du, Jiarui Zhao, Xusheng Huang, Fang Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurodegenerative disease management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yahui ZhuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiongming BaiDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Hongfen WangDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Mao LiDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Fei YangDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Xinyuan PangDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Rongrong DuDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Jiarui ZhaoDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Xusheng HuangDepartment of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Fang CuiDepartment of Neurology, Hainan Hospital of PLA General Hospital, Sanya, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe investigated the relationship between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFRdiff) and amyotrophic lateral sclerosis (ALS) outcomes.

methodsWe enrolled ALS patients diagnosed between January 2014 and December 2019. Experienced neurologists followed up the participants until January 2022. Absolute difference between eGFR (eGFRabdiff) and relative difference between eGFR (eGFRrediff) were obtained. Cox proportional hazard models were used to evaluate the relationship between eGFRdiff and ALS survival.

resultsNegative eGFRabdiff were common in the patients (74.7%). For each SD increase of eGFRabdiff, the risk of poor prognosis for ALS patients decreased by 1.9% (HR, 0.981; 95% CI, 0.973-0.989). For each 10% increment in eGFRrediff, the risk of poor prognosis for ALS patients decreased by 17.7% (HR, 0.823; 95% CI, 754-0.898).

conclusionsWe found that large eGFRdiff was associated with poor prognosis in ALS. Monitoring eGFRdiff in ALS population facilitates prognostic stratification assessment and precise management.

Indexed as

Amyotrophic Lateral SclerosisCreatinineCystatin CGlomerular Filtration RateAdultAgedBiomarkersCohort StudiesFemaleHumansMaleMiddle AgedPrognosisBiomarkersCreatinineCystatin Camyotrophic lateral sclerosisCreatininecystatin Cglomerular filtration ratesurvival

Identifiers

PMID40898684
PMCPMC13011588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.